Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
21 nov. 2019 08h00 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 150,000 shares of...
Onconova Announces Five Presentations on Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2019 Annual Meeting & Exposition
07 nov. 2019 07h30 HE
|
Onconova Therapeutics, Inc.
Oral presentation will feature efficacy and safety data from Expanded Phase 2 Trial of oral rigosertib in combination with azacitidine Four poster presentations to feature: biomarker...
Geron Corporation Reports Third Quarter 2019 Financial Results and Recent Events
06 nov. 2019 16h10 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as...
Geron Announces Two Poster Presentations at Upcoming American Society of Hematology Annual Meeting
06 nov. 2019 09h18 HE
|
Geron Corporation
MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts related to imetelstat, the Company’s first-in-class telomerase inhibitor,...
Geron to Announce Third Quarter Financial Results on November 6, 2019
31 oct. 2019 08h00 HE
|
Geron Corporation
MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2019 financial results after the market closes on...
Onconova Affirms Planned Completion of Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes by 1H20 And Provides Research & Development Update
24 oct. 2019 07h30 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
17 oct. 2019 16h10 HE
|
Geron Corporation
MENLO PARK, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 200,000 shares of...
Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes
10 oct. 2019 17h30 HE
|
Geron Corporation
MENLO PARK, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate...
Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis
30 sept. 2019 16h19 HE
|
Geron Corporation
MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation...
First Substantial Customer: Tennessee Oncology Internalizes Precipio’s HemeScreen™
30 sept. 2019 11h10 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Tennessee Oncology has selected Precipio’s HemeScreen RUO assay as...